Perception of Illness Turkish Validity and Reliability Study

December 22, 2020 updated by: MİNE PEKESEN KURTÇA, Pamukkale University

Validity and Reliability Study of Turkish Adaptation of The Disease Perception Scale in Rheumatic Diseases

In chronic diseases such as rheumatic diseases, it is important to direct the treatment of the disease and to evaluate the disease perception in terms of the course of the disease. As a result of this study, this questionnaire, which will help us gain information about the perception of the disease specific to rheumatic diseases, will be translated into Turkish.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Disease perception is the cognitive aspect of the disease state. Although they experience the same disease in a certain period of their lives, the methods of meeting the disease and coping with the disease differ. Patients try to explain their illnesses in the light of their personal experiences, knowledge, values, beliefs and needs. People create cognitive models to explain and predict events in the outside world. Patients also develop similar patterns of symptoms of transient or long-term disease. Leventhal et al. suggested that patients formed their own coping mechanisms with these cognitive models and developed the self-regulation theory. According to this theory, people create schemas about illness and life-threatening situations in their minds with the information presented to them from concrete and abstract sources. These cognitive models also include beliefs about treatment and control of the condition.

The World Health Organization (WHO) has classified more than 200 musculoskeletal diseases, the most common being rheumatoid arthritis and osteoarthritis. The biopsychosocial model has been drawing attention in rheumatological rehabilitation in recent years. This model acknowledges that the experiences and symptoms of the disease are affected by biological, psychological and social factors. The dysfunction is not only related to the severity of the disease, but also to how the disease is perceived. The patient's beliefs and perceptions about his illness show how the illness affects him both physically and emotionally. Disease perception is based not only on symptoms but also on disease-related consequences, concerns, and past illness experiences of the patient. Recent studies emphasize the importance of disease perception in explaining the difference in treatment outcomes in chronic diseases, including rheumatic diseases.

It was planned to determine the validity and reliability of the Disease Perception Scale in Rheumatic Diseases due to the importance of treatment in rheumatic diseases and the evaluation of disease perception in terms of the course of the disease.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Samsun, Turkey
        • Mine Pekesen Kurtca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Rheumatoid Arthritis, Spondyloarthropathies, Fibromyalgia, Reactive Arthritis, Sjögren Syndrome, Systemic Lupus Erythematosus

Description

Inclusion Criteria:

  • Volunteer.
  • To be diagnosed with any of the rheumatic diseases (Rheumatoid Arthritis, Spondyloarthropathies, Fibromyalgia, Reactive Arthritis, Sjögren Syndrome, Systemic Lupus Erythematosus) by a specialist.

Exclusion Criteria:

  • Being diagnosed with a chronic disease other than rheumatic disease that requires regular medication.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
1) Health Assessment Questionnaire (HAQ)
Time Frame: The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.
HAQ has sub-sections that evaluate the inadequacy index (20 questions), pain (one question) and global health status (one question). The last week is questioned in the survey.There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). For each section the score given to that section is the worst score within the section, i.e. if one question is scored 1 and another 2, then the score for the section is 2.
The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.
2) Nottingham Health Profile
Time Frame: The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.
Nottingham Health Profile (NHP) is a measurement tool that evaluates the health problems of individuals and how these problems affect their daily activities.The questionnaire is divided into two parts. The first parts comprises 38 questions in six categories: sleep, physical mobility, energy, pain, emotional reactions, and social isolation. This first section is weighted to reflect how severe an impact the respondent thinks their health is having on the above areas of life. The second part of the NHP is made up of seven statements about areas of life that are commonly affected by health: paid employment, jobs around the house, social life, personal relationships, sex life, hobbies and interests, and holidays. Scores on the NHP can range from 0 i.e. no distress to 100 i.e severe distress.
The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.
Rheumatic Disease Illness Perception Questionnaire
Time Frame: The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.
It is a questionnaire consisting of 11 questions that evaluates the cognitive and emotional perception of the disease in individuals with rheumatic disease. The cause and consequences of the disease, the extent to which the patient understands his / her illness, and the emotional changes in the course of the disease and the disease are questioned.
The first test is made when the patient is directed by the physician. Seventh day after test, re-test is made. For test-retest, the questionnaire will be repeated 7 days apart.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Pamukkale University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Izmir Katip Celebi University
Akdeniz University
Ondokuz Mayıs University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: BİLGE BAŞAKCI CALIK, Assoc. Prof., PAMUKKALE UNIVERTSITY
  • Study Chair: SABAHAT YAPRAK CETİN, Asst. Prof., Akdeniz University
  • Study Chair: VELİ ÇOBANKARA, Prof.Dr., Pamukkale University
  • Study Chair: AYŞE AYAN, Assoc.Prof., ANTALYA EDUCATION RESEARCH HOSPITAL

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 31, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 15, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 22, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 28, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 28, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 22, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ONDOKUZMAYISU

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We would like to share study protocol and statistical analysis (SAP).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings